May 25, 2023 9:00 am EDT Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
May 23, 2023 6:00 am EDT Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
May 17, 2023 8:00 am EDT Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank
May 9, 2023 4:05 pm EDT Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update
Apr 26, 2023 8:00 am EDT Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023
Apr 20, 2023 8:00 am EDT Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline
Apr 14, 2023 8:00 am EDT Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference
Mar 29, 2023 8:00 am EDT Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation